|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: WDR7 |
Gene summary for WDR7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | WDR7 | Gene ID | 23335 |
| Gene name | WD repeat domain 7 | |
| Gene Alias | TRAG | |
| Cytomap | 18q21.31 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9Y4E6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23335 | WDR7 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 1.77e-15 | 6.80e-01 | -0.2116 |
| 23335 | WDR7 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 2.14e-02 | 4.43e-01 | -0.2107 |
| 23335 | WDR7 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 8.73e-13 | 6.53e-01 | -0.2119 |
| 23335 | WDR7 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 3.62e-04 | 2.64e-01 | -0.0166 |
| 23335 | WDR7 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 4.15e-02 | 1.89e-01 | -0.0132 |
| 23335 | WDR7 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 1.56e-03 | 2.09e-01 | -0.013 |
| 23335 | WDR7 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 4.17e-02 | 2.01e-01 | -0.0121 |
| 23335 | WDR7 | HTA12-15-2 | Human | Pancreas | PDAC | 3.34e-04 | 4.26e-01 | 0.2315 |
| 23335 | WDR7 | HTA12-23-1 | Human | Pancreas | PDAC | 1.68e-12 | 9.53e-01 | 0.3405 |
| 23335 | WDR7 | HTA12-26-1 | Human | Pancreas | PDAC | 1.16e-23 | 1.02e+00 | 0.3728 |
| 23335 | WDR7 | HTA12-29-1 | Human | Pancreas | PDAC | 2.73e-37 | 8.39e-01 | 0.3722 |
| 23335 | WDR7 | HTA12-30-1 | Human | Pancreas | PDAC | 4.63e-02 | 9.00e-01 | 0.3671 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00430624 | Esophagus | ESCC | extracellular structure organization | 171/8552 | 302/18723 | 7.73e-05 | 5.76e-04 | 171 |
| GO:00452294 | Esophagus | ESCC | external encapsulating structure organization | 172/8552 | 304/18723 | 7.80e-05 | 5.80e-04 | 172 |
| GO:00335234 | Esophagus | ESCC | histone H2B ubiquitination | 12/8552 | 12/18723 | 8.21e-05 | 6.01e-04 | 12 |
| GO:00018253 | Esophagus | ESCC | blastocyst formation | 29/8552 | 38/18723 | 1.18e-04 | 8.13e-04 | 29 |
| GO:005067318 | Esophagus | ESCC | epithelial cell proliferation | 238/8552 | 437/18723 | 1.19e-04 | 8.20e-04 | 238 |
| GO:00459432 | Esophagus | ESCC | positive regulation of transcription by RNA polymerase I | 19/8552 | 23/18723 | 3.12e-04 | 1.85e-03 | 19 |
| GO:00308506 | Esophagus | ESCC | prostate gland development | 32/8552 | 45/18723 | 4.87e-04 | 2.70e-03 | 32 |
| GO:005067817 | Esophagus | ESCC | regulation of epithelial cell proliferation | 206/8552 | 381/18723 | 5.51e-04 | 3.02e-03 | 206 |
| GO:00311227 | Esophagus | ESCC | cytoplasmic microtubule organization | 38/8552 | 56/18723 | 6.60e-04 | 3.50e-03 | 38 |
| GO:00331824 | Esophagus | ESCC | regulation of histone ubiquitination | 11/8552 | 12/18723 | 1.26e-03 | 6.06e-03 | 11 |
| GO:2000234 | Esophagus | ESCC | positive regulation of rRNA processing | 9/8552 | 10/18723 | 5.09e-03 | 1.92e-02 | 9 |
| GO:00226172 | Esophagus | ESCC | extracellular matrix disassembly | 39/8552 | 63/18723 | 6.92e-03 | 2.52e-02 | 39 |
| GO:00016559 | Esophagus | ESCC | urogenital system development | 177/8552 | 338/18723 | 7.51e-03 | 2.69e-02 | 177 |
| GO:00165703 | Liver | NAFLD | histone modification | 90/1882 | 463/18723 | 5.74e-10 | 1.28e-07 | 90 |
| GO:00726597 | Liver | NAFLD | protein localization to plasma membrane | 51/1882 | 284/18723 | 2.97e-05 | 7.83e-04 | 51 |
| GO:19033207 | Liver | NAFLD | regulation of protein modification by small protein conjugation or removal | 44/1882 | 242/18723 | 7.53e-05 | 1.56e-03 | 44 |
| GO:19907786 | Liver | NAFLD | protein localization to cell periphery | 56/1882 | 333/18723 | 8.29e-05 | 1.69e-03 | 56 |
| GO:00313967 | Liver | NAFLD | regulation of protein ubiquitination | 38/1882 | 210/18723 | 2.49e-04 | 4.12e-03 | 38 |
| GO:00310563 | Liver | NAFLD | regulation of histone modification | 29/1882 | 152/18723 | 5.30e-04 | 7.31e-03 | 29 |
| GO:00510526 | Liver | NAFLD | regulation of DNA metabolic process | 56/1882 | 359/18723 | 5.95e-04 | 7.92e-03 | 56 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| WDR7 | SNV | Missense_Mutation | c.2250N>G | p.Ile750Met | p.I750M | Q9Y4E6 | protein_coding | tolerated(0.19) | benign(0.015) | TCGA-A1-A0SH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | tc | SD | |
| WDR7 | SNV | Missense_Mutation | c.2882C>G | p.Ala961Gly | p.A961G | Q9Y4E6 | protein_coding | tolerated(0.06) | benign(0.017) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | ||
| WDR7 | SNV | Missense_Mutation | rs778537690 | c.1597N>G | p.Ile533Val | p.I533V | Q9Y4E6 | protein_coding | tolerated(0.52) | benign(0) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| WDR7 | SNV | Missense_Mutation | c.686N>T | p.Ser229Leu | p.S229L | Q9Y4E6 | protein_coding | deleterious(0.04) | benign(0.023) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD | |
| WDR7 | SNV | Missense_Mutation | c.3245G>C | p.Gly1082Ala | p.G1082A | Q9Y4E6 | protein_coding | tolerated(0.32) | benign(0.024) | TCGA-A8-A07B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| WDR7 | SNV | Missense_Mutation | novel | c.1208G>T | p.Ser403Ile | p.S403I | Q9Y4E6 | protein_coding | tolerated(0.16) | benign(0) | TCGA-AR-A24U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| WDR7 | SNV | Missense_Mutation | c.1616A>T | p.Asp539Val | p.D539V | Q9Y4E6 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-B6-A0RH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| WDR7 | SNV | Missense_Mutation | c.1195G>T | p.Val399Leu | p.V399L | Q9Y4E6 | protein_coding | tolerated(0.78) | benign(0) | TCGA-BH-A18T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| WDR7 | SNV | Missense_Mutation | novel | c.2219N>T | p.Ala740Val | p.A740V | Q9Y4E6 | protein_coding | tolerated(0.13) | benign(0.021) | TCGA-C8-A8HR-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
| WDR7 | SNV | Missense_Mutation | c.1991G>C | p.Gly664Ala | p.G664A | Q9Y4E6 | protein_coding | tolerated(0.12) | possibly_damaging(0.775) | TCGA-EW-A1OV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |